{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:24:24Z","timestamp":1791221064325,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>Landiolol is an ultra-short-acting, highly cardio-selective, \u03b2-blocker, that is currently approved for clinical use in Japan and the European Union, for the treatment of tachyarrhythmias. Landiolol is highly cardio-selective with high \u03b21 selectivity and receptor affinity, resulting in a more potent chronotropic effect and less potent hypotensive effect compared with other \u03b2-blockers such as esmolol and propranolol. Based on the recent randomized controlled trials, low-dose landiolol may have a beneficial role in the prevention and management of postoperative atrial fibrillation following noncardiac and cardiac surgeries, including on-pump and off-pump coronary artery bypass grafting and valve surgery. Additionally, landiolol may have potential utility for myocardial salvage and prevention of postpercutaneous coronary intervention myocardial infarction. Furthermore, the use of landiolol may also have a therapeutic effect for rate control of sepsis-related tachyarrhythmias. Positive results of recent randomized controlled trials should continue to inspire clinicians to conduct further, larger studies, to find new potential clinical applications for this novel drug.<\/jats:p>","DOI":"10.1097\/crd.0000000000000555","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T01:00:09Z","timestamp":1682470809000},"page":"468-472","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Landiolol: An Ultra-Short-Acting \u03b2-Blocker"],"prefix":"10.1097","volume":"32","author":[{"given":"Shiavax J.","family":"Rao","sequence":"first","affiliation":[{"name":"Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Kanwal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amreen","family":"Kanwal","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandrina","family":"Danilov","sequence":"additional","affiliation":[{"name":"New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center, Valhalla, NY"},{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40265-013-0077-4","article-title":"Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias.","volume":"73","author":"Plosker","year":"2013","journal-title":"Drugs"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1248\/cpb.40.1462","article-title":"Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101.","volume":"40","author":"Iguchi","year":"1992","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fphar.2013.00150","article-title":"Characteristic interactivity of landiolol, an ultra-short-acting highly selective \u03b21-blocker, with biomimetic membranes: comparisons with \u03b21-selective esmolol and non-selective propranolol and alprenolol.","volume":"4","author":"Tsuchiya","year":"2013","journal-title":"Front Pharmacol"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-018-0883-9","article-title":"Landiolol: a review in tachyarrhythmias.","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/BF03016588","article-title":"In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol.","volume":"48","author":"Sasao","year":"2001","journal-title":"Can J Anaesth J Can Anesth"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00540-008-0640-4","article-title":"Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts.","volume":"22","author":"Ikeshita","year":"2008","journal-title":"J Anesth"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1254\/jphs.11202FP","article-title":"Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts.","volume":"118","author":"Shibata","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.116.232884","article-title":"Comparison of the \u03b2-adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions.","volume":"359","author":"Nasrollahi-Shirazi","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00228-016-2176-0","article-title":"Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.","volume":"73","author":"Krumpl","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FJC.0000000000000495","article-title":"Pharmacodynamic and -kinetic behavior of low-, intermediate-, and high-dose landiolol during long-term infusion in whites.","volume":"70","author":"Krumpl","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/FJC.0000000000000554","article-title":"Pharmacokinetics and pharmacodynamics of low-, intermediate-, and high-dose landiolol and esmolol during long-term infusion in healthy whites.","volume":"71","author":"Krumpl","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2133\/dmpk.12.31","article-title":"Studies on the metabolic fate of ultra short acting.BETA.1 blocker ONO-1101. (3). Metabolism and protein binding.","volume":"12","author":"Tsunekawa","year":"1997","journal-title":"Drug Metab Pharmacokinet"},{"key":"R16-20250619","first-page":"64","article-title":"Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group.","volume":"92","author":"Krumpl","year":"2016","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00595-013-0616-3","article-title":"Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients.","volume":"44","author":"Ojima","year":"2014","journal-title":"Surg Today"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S0022-5223(03)00974-7","article-title":"Atrial fibrillation after esophagectomy is a marker for postoperative morbidity and mortality.","volume":"126","author":"Murthy","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10388-016-0553-5","article-title":"A randomized, open label study of the efficacy of prophylactic 24-h low-dose landiolol for atrial fibrillation in transthoracic esophagectomy.","volume":"14","author":"Yoshida","year":"2017","journal-title":"Esophagus"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/bjs.10548","article-title":"Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer.","volume":"104","author":"Ojima","year":"2017","journal-title":"Br J Surg"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jclinane.2017.01.036","article-title":"The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: a randomized controlled clinical trial.","volume":"38","author":"Horikoshi","year":"2017","journal-title":"J Clin Anesth"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jtcvs.2010.10.045","article-title":"Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial.","volume":"141","author":"Sezai","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jtcvs.2012.06.042","article-title":"Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study.","volume":"144","author":"Sezai","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R24-20250619","first-page":"369","article-title":"Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery.","volume":"53","author":"Fujii","year":"2012","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0218492312451166","article-title":"Perioperative use of a beta blocker in coronary artery bypass grafting.","volume":"21","author":"Ogawa","year":"2013","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"R26-20250619","first-page":"129","article-title":"Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting.","volume":"20","author":"Nagaoka","year":"2014","journal-title":"Ann Thorac Cardiovasc Surg Off J Assoc Thorac Cardiovasc Surg Asia"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1536\/ihj.53.359","article-title":"Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery.","volume":"53","author":"Sakaguchi","year":"2012","journal-title":"Int Heart J"},{"key":"R28-20250619","first-page":"1097","article-title":"Landiolol, an ultra-short-acting \u03b21","volume":"76","author":"Sakamoto","year":"2012","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1253\/circj.CJ-11-0947","article-title":"Randomized study on the efficacy and safety of landiolol, an ultra-short-acting.BETA.1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.","volume":"76","author":"Hanada","year":"2012","journal-title":"Circ J"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ijcard.2012.04.096","article-title":"Intracoronary followed by intravenous administration of the short-acting \u03b2-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention.","volume":"167","author":"Park","year":"2013","journal-title":"Int J Cardiol"},{"key":"R31-20250619","first-page":"289","article-title":"Efficacy and safety of early intravenous landiolol on myocardial salvage in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention: a randomized study.","volume":"75","author":"Miyamoto","year":"2021","journal-title":"Acta Med Okayama"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/CCM.0b013e318174db05","article-title":"Actual incidence of global left ventricular hypokinesia in adult septic shock.","volume":"36","author":"Vieillard-Baron","year":"2008","journal-title":"Crit Care Med"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1378\/chest.80.5.579","article-title":"An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy.","volume":"80","author":"Calvin","year":"1981","journal-title":"Chest"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CRD.0000000000000301","article-title":"Myocardial depression in sepsis: beneficial adaptation or sequelae that requires treatment?","volume":"28","author":"Rumery","year":"2020","journal-title":"Cardiol Rev"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5492\/wjccm.v4.i3.251","article-title":"Landiolol, an ultra-short-acting \u03b21-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis.","volume":"4","author":"Okajima","year":"2015","journal-title":"World J Crit Care Med"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1213\/01.ANE.0000140814.28118.6F","article-title":"Successful management of tachycardiac atrial fibrillation in a septic patient with landiolol.","volume":"100","author":"Yoshida","year":"2005","journal-title":"Anesth Analg"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(20)30037-0","article-title":"Efficacy and safety of landiolol, an ultra-short-acting \u03b21-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.","volume":"8","author":"Kakihana","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s13063-018-3024-6","article-title":"Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial.","volume":"19","author":"Unger","year":"2018","journal-title":"Trials"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:03:17Z","timestamp":1750348997000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000555","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}